<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613270</url>
  </required_header>
  <id_info>
    <org_study_id>PekingUMCH-FES-BC-1</org_study_id>
    <nct_id>NCT05613270</nct_id>
  </id_info>
  <brief_title>Characterizing Breast Cancer With 18F-FES PET/CT</brief_title>
  <official_title>A Prospective Pilot Study to Explore Performance and Efficacy of 18F-FES PET/CT in ER-positive Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      18F-fluoroestradiol (FES) is radioactive labeled estradiol, developed for in vivo&#xD;
      visualization of estrogen receptor (ER) using positron emission tomography (PET). In this&#xD;
      prospective study, 18F-FES PET/CT will be used to evaluate ER activity of metastatic disease&#xD;
      and their potential sensitivity to endocrine therapy in ER-positive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value of 18F-FES in BC</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The max standard uptake value (SUVmax) was measured in the breast cancer lesions on 18F-FES PET/CT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesions detected by 18F-FES PET/CT</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The number of target lesions was calculated by 18F-FES PET/CT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compared with 18F-FDG PET/CT</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The number of lesions detected by 18F-FES PET/CT was compared with 18F-FDG PET/CT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluate overall survival (OS) in patients receiving regimens containing endocrine therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>18F-FES PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject 18F-FES and then perform PET/CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-FES PET/CT scan</intervention_name>
    <description>Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.</description>
    <arm_group_label>18F-FES PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  suspected or confirmed metastatic ER-positive breast cancer;&#xD;
&#xD;
          -  18F-FDG PET/CT within two weeks;&#xD;
&#xD;
          -  signed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy;&#xD;
&#xD;
          -  breastfeeding;&#xD;
&#xD;
          -  any medical condition that in the opinion of the investigator may significantly&#xD;
             interfere with study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Huo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhixin Hao, M.D.</last_name>
    <phone>+86-18401649136</phone>
    <email>zxhaonm@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Huo, M.D.</last_name>
    <phone>+86-13910801986</phone>
    <email>huoli@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhixin Hao, M.D.</last_name>
      <phone>+86-18401649136</phone>
      <email>zxhaonm@outlook.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Huo, M.D.</last_name>
      <phone>+86-13910801986</phone>
      <email>huoli@pumch.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Li Huo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 4, 2022</last_update_submitted>
  <last_update_submitted_qc>November 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

